These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 2223270)

  • 1. [Alteration of prolactin secretion after transsphenoidal adenomectomy for prolactinomas].
    Yokoyama M
    No To Shinkei; 1990 Aug; 42(8):773-9. PubMed ID: 2223270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolactin secretion after surgery or bromocriptine treatment of prolactinoma.
    De Leo V; Petraglia F; Sardelli S; Danero S; Genazzani AR; D'Antona N
    Obstet Gynecol; 1987 Jan; 69(1):99-103. PubMed ID: 3099236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors.
    Schlechte JA; Sherman BM; Chapler FK; VanGilder J
    J Clin Endocrinol Metab; 1986 Jun; 62(6):1296-301. PubMed ID: 3084539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical treatment of prolactinomas. Short- and long-term results, prognostic factors.
    Charpentier G; de Plunkett T; Jedynak P; Peillon F; Le Gentil P; Racadot J; Visot A; Derome P
    Horm Res; 1985; 22(3):222-7. PubMed ID: 4054842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests.
    Webster J; Page MD; Bevan JS; Richards SH; Douglas-Jones AG; Scanlon MF
    Clin Endocrinol (Oxf); 1992 Jan; 36(1):35-44. PubMed ID: 1559298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
    Morange I; Barlier A; Pellegrini I; Brue T; Enjalbert A; Jaquet P
    Eur J Endocrinol; 1996 Oct; 135(4):413-20. PubMed ID: 8921822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up.
    Wu ZB; Yu CJ; Su ZP; Zhuge QC; Wu JS; Zheng WM
    J Neurosurg; 2006 Jan; 104(1):54-61. PubMed ID: 16509147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas.
    Arafah BM; Nekl KE; Gold RS; Selman WR
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3507-12. PubMed ID: 8530591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK; Vance ML; Boulos PT; Laws ER
    Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Giant prolactinomas: clinical management and long-term follow up.
    Shrivastava RK; Arginteanu MS; King WA; Post KD
    J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
    Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study.
    Wei L; Wei X
    Hormones (Athens); 2021 Dec; 20(4):745-752. PubMed ID: 34275094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
    Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
    Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
    Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the prolactin serum isoforms secreted by a pituitary adenoma associated with therapy.
    Morán C; Tena G; Fonseca ME; Ochoa R; Bermúdez JA; Zárate A
    Arch Med Res; 1994; 25(1):1-3. PubMed ID: 8019107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up.
    Hildebrandt G; Bauer T; Stracke H; Fassbender WJ; Mueller HW; Agnoli AL; Federlin K; Roosen K
    Zentralbl Neurochir; 1992; 53(3):123-34. PubMed ID: 1414079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
    Montini M; Pagani G; Gianola D; Pagani MD; Salmoiraghi M; Ferrari L; Lancranjan I
    J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
    Primeau V; Raftopoulos C; Maiter D
    Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRH.
    Bevan JS; Burke CW
    Clin Endocrinol (Oxf); 1989 Jun; 30(6):667-80. PubMed ID: 2512041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender-related differences in prolactin secretion in pituitary prolactinomas.
    Nishioka H; Haraoka J; Akada K; Azuma S
    Neuroradiology; 2002 May; 44(5):407-10. PubMed ID: 12012125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.